display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positive
la/mBC - HER2 positive - 2nd Line (L2)
antibody–drug conjugate
trastuzumab deruxtecan DESTINY Breast03
trastuzumab emtansine EMILIA

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons